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Summary 
 
Cytochromes P450 (CYP) constitute the major enzymatic system for metabolism of xenobiotics. 
Here we demonstrate that transcriptional activation of CYPs by the drug-sensing nuclear receptors 
pregnane X receptor (PXR), constitutive androstane receptor (CAR) and the chicken xenobiotic 
receptor (CXR) can be modulated by endogenous cholesterol and bile acids. Bile acids induce the 
chicken drug-activated CYP2H1 via CXR whereas the hydroxylated metabolites of bile acids and 
oxysterols inhibit drug-induction. The cholesterol-sensing liver X receptor (LXR) competes with 
CXR, PXR or CAR for regulation of drug-responsive enhancers from chicken CYP2H1, human 
CYP3A4 or human CYP2B6, respectively. Thus, not only cholesterol 7-hydroxylase (CYP7A1), 
but also drug-inducible CYPs are diametrically affected by these receptors. Our findings reveal new 
insights into the increasingly complex network of nuclear receptors regulating lipid homeostasis and 
drug metabolism. 
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Introduction 
 
Cytochromes P450 (CYPs)1 are heme-containing enzymes responsible for the hydroxylation of 
lipophilic substrates in all species. In the liver, a subset of members of the CYP gene superfamily 
metabolize xenobiotics such as drugs, food additives and pollutants (1). Some of these CYPs can be 
transcriptionally regulated by their own substrates and by other compounds. The barbiturate 
phenobarbital (PB) represents a class of inducers that activate predominantly the CYP2B and 
CYP2C subfamilies whereas the glucocorticoid dexamethasone and the antibiotic rifampicin 
exemplify drugs that elevate CYP3A levels in man. Induction of drug metabolism has important 
clinical consequences, causing altered pharmacokinetics of drugs and carcinogens, drug-drug 
interactions and changes in the metabolism of steroids, vitamin D and other endogenous 
compounds. Other types of hepatic CYPs occupy key positions in the biosynthesis and metabolism 
of numerous endogenous molecules including steroids, bile acids, fatty acids, prostaglandins, 
leukotrienes, biogenic amines or retinoids. As examples, CYP51 converts lanosterol into cholesterol 
whereas CYP7A1 catalyzes the first step of cholesterol metabolism into bile acids (2). Like 
xenobiotic-metabolizing CYPs, some of the CYPs that hydroxylate endogenous substrates are also 
regulated transcriptionally by their substrates or metabolites. In the mouse, CYP7A1 is induced by 
oxysterols and inhibited by bile acids (3). 
 
Transcriptional regulation of many CYPs is carried out by members of the gene superfamily of 
nuclear receptors (3,4). The relative lipophilicity and small size of inducer compounds allows either 
direct diffusion or facilitated transport into the cell and interaction with specific intracellular 
receptors which then bind to their respective DNA-recognition elements arranged as repeats of 
hexamer halfsites in the 5’-flanking regions of CYPs (5,6). The nuclear receptors liver X receptor 
(LXR) and the farnesoid X receptor (FXR) bind oxysterols and bile acids, respectively, and are key 
players in the regulation of CYP7A1 (3). The transcriptional activation of CYP7A1 by LXR in 
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rodents is counteracted by high bile acid levels that activate FXR. FXR subsequently increases the 
transcription of the small heterodimerization partner (SHP) that acts as an inhibitor of several 
nuclear receptors, including LXR (7,8). 
 
Although induction of CYPs by PB has been described over 40 years ago, our understanding of the 
molecular mechanism is still fragmentary. Recently, the nuclear receptors constitutive androstane 
receptor (CAR), pregnane X receptor (PXR), alternatively called steroid and xenobiotic receptor 
(SXR) or pregnane-activated receptor (PAR), and chicken xenobiotic receptor (CXR) were 
discovered to be involved in drug-induction of CYP2Bs, CYP3As and CYP2H1 in man, mouse and 
chicken, respectively (4-6,9). In mammals, CAR and PXR exhibit overlapping substrate and DNA-
recognition specificity and the exact contribution of these two receptors to drug-induction has not 
been fully elucidated (10-13). In chicken, only one xenobiotic-sensing orphan nuclear receptor has 
been identified. It might constitute the ancestral gene that diverged into CAR and PXR in mammals 
(9). In spite of this apparent difference, the molecular mechanism of drug-mediated CYP induction 
is conserved at the level of both nuclear receptors and DNA-recognition elements from birds to man 
(9,14-16). 
 
Apparently, many CYPs are responsible for maintaining both lipid homeostasis and detoxification 
of lipid-soluble drugs and xenobiotics (4). Accordingly, the xenosensor PXR is also activated by 
endogenous bile acids and involved in hepatic detoxification of excess bile acid levels acids (13,17). 
In this report, we describe experiments concerning the role of xenobiotic-sensing nuclear receptors 
in lipid homeostasis as well as the role of cholesterol- and bile acid-sensing nuclear receptors in 
drug-metabolism. Moreover, we present a hypothesis on how these nuclear receptors might interact 
with each other and thus provide a sensitive regulatory network that controls both lipid and 
xenobiotic-levels. These findings also provide insight into the evolution of these systems and 
suggests that our body might recognize lipophilic xenobiotics as a kind of “toxic bile acids”. 
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Experimental Procedures 
 
Plasmids. 
Full-length receptor coding sequences from chicken CXR, 9-cis retinoic acid receptor (RXR), 
FXR and LXR were amplified and subcloned into the expression vector pSG5 (Stratagene, Basel, 
Switzerland). Chicken CXR (amino acids 97-391), FXR (amino acid 194-473) and LXR (amino 
acids 126-409) Ligand bindind domains (LBD) fused to the yeast GAL4 transcription factor DBD 
were obtained by PCR-amplification of the LBDs of the nuclear receptors and subsequent 
subcloning of the PCR-products in-frame into the expression plasmid pA4.7, a kind gift from Dr. A. 
Kralli, Division of Biochemistry, Biozentrum, Basel, Switzerland. An N-terminal hemagglutinin 
(HA)-tag was produced using the oligonucleotides 5’-AAT TCC CAT GTA CCC ATA CGA TGT 
TCC AGA TTA CGC TG-3’ and 5’-AAT TCA GCG TAA TCT GGA ACA TCG TAT GGG TAC 
ATG GG-3’ synthesized by Microsynth, Balgach, Switzerland. The double-stranded 
oligonucleotide was ligated into the EcoRI-site of the pSG5-CXR expression vector. The (UAS)5-
tk-CAT reporter plasmid was generously provided by Dr. S. A. Kliewer, Department of Molecular 
Endocrinology, GlaxoSmithKline Research and Development, Research Triangle Park, NC. 
Oligonucleotides for the wildtype CYP2B6 51-bp PB-responsive enhancer module (PBREM) and 
the corresponding 51-bp where the hexamer halfsites of the two DR-4 elements were mutated into 
SacII and EcoRV sites, respectively, were synthesized by Microsynth, Balgach, Switzerland. 
Similarly, a wildtype ER-6 element from the CYP3A4 promoter and a corresponding element with 
mutations in the intrinsic DR-4 element were obtained. Human LXR in the CMX-expression 
vector was a kind gift of Dr. R. M. Evans, The Salk Institute, San Diego, CA. Human RXR 
expression plasmid was generously provided by Dr. P. Chambon, IGBMC, Université Louis 
Pasteur, Illkirch, France. A pGL3basic-plasmid containing 13 kb of the human CYP3A4 5’-flanking 
region was a kind gift of Dr. C. Liddle, University of Sydney at Westmead Hospital, Westmead, 
Australia. This construct was digested with XbaI and SpeI and the resulting 343-bp fragment further 
Page 7 of 27 
cut with HincII. The 228-bp xenobiotic-responsive enhancer module (XREM) was subsequently 
used in electromobility shift assays and has been described (18). 
 
Culture and Transfection of LMH Cells. 
Cultivation of LMH cells in William’s E medium and transfection with FuGENE 6 Transfection 
Reagent (Roche Molecular Biochemicals, Rotkreuz, Switzerland) were performed as described 
(16). Before transfection, cells were kept in serum-free medium for 24 hours. The cells were then 
plated on 6-well dishes and medium was replaced 4 hours after transfection by induction- or 
control-medium, respectively, both lacking fetal calf serum. 
 
Analysis of Reporter Gene Expression. 
16 hours after drug treatment, the cells were harvested and non-radioactive chloramphenicol 
acetyltransferase (CAT) assays were performed using the CAT-ELISA kit according to the manual 
of the supplier (Roche Molecular Biochemicals, Rotkreuz, Switzerland). Cell extracts were also 
used for the determination of protein concentration using the ESL protein assay for normalization of 
specific CAT expression to total protein content (Roche Molecular Biochemicals, Rotkreuz, 
Switzerland). 
 
Transcriptional activation assays. 
Transfection and drug treatment of CV-1 cells was performed as described (16). Cell extracts were 
prepared, assayed for CAT using a CAT-ELISA kit (Roche Molecular Biochemicals, Rotkreuz, 
Switzerland) and -galactosidase activities were determined. CAT concentrations were then 
normalized against -galactosidase values in order to compensate for varying transfection 
efficiencies. 
 
Electromobility-shift assays. 
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Electromobility-shift assays were performed as published (16). To test for supershifts, 0.5 l of 
either monoclonal anti-mouse-RXR rabbit antibody (kindly provided by Dr. P. Chambon, IGBMC, 
Université Louis Pasteur, Illkirch, France) or of a 200 g IgG/ml anti-HA high affinity rat 
monoclonal antibody solution (Roche Molecular Biochemicals, Rotkreuz, Switzerland) were added 
to the reaction mix. 
 
Amplification of nuclear receptors from CV-1 cDNA. 
CV-1 cell cDNA was used in PCR reactions for 40 cycles using an annealing temperature of 61.5°C 
with the following primers: human CAR 5'-GAG GGC TGC AAG GGT TTC TTC AGG AGA-3' 
and 5'-CAG CAG GCC TAG CAA CTT CGC ATA CAG A-3', human PXR 5'-ATC AAG CGG 
AAG AAA AGTGAA CGG ACA G-3' and 5'-GAG GGG CGT AGC AAA GGG GTG TAT G-3', 
human LXR 5'-CAG AGC CCC CTT CAG AAC CCA CAG AGA T-3' and 5'-GAG CAA GGC 
AAA CTC GGC ATC ATT GAG-3', human LXR 5'-CAC AGT CAC AGT CGC AGT CAC 
CTG-3' and 5'-GAG AAC TCG AAG ATG GGG TTG ATG AAC T-3'. human FXR 5'-GTT TCT 
ACC CCC AGC AGC CTG AAG AGT G-3' and 5'-CAG CGT GGT GAT GAT TGA ATG TCC 
GTA A-3' and human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 5'-CGG GAA GCT 
TGT CAT CAA TGG AAA TC-3' and 5'-GCC AAA TTC GTT GTC ATA CCA GGA AAT G-3'. 
Bands or regions of the expected sizes (864-bp for CAR, 900-bp for PXR, 869-bp for LXR, 532-
bp for LXR, 1134-bp for FXR and 766-bp for GAPDH, respectively) were excised from the gel, 
subcloned and sequenced. 
 
Northern blots. 
A probe for chicken CYP7A1 was amplified from chicken cDNA using degenerate primers based 
on the mammalian CYP7A1 sequences and verified by sequencing. A more comprehensive analysis 
and characterization of full-length chicken CYP7A1 mRNA will be published elsewhere. Northern 
hybridizations were carried out as described (16). 
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Results 
 
Oxysterols and bile acids modify drug-induction 
In rat, CYP2B2 mRNA levels are elevated when blocking cholesterol biosynthesis using the 
squalene synthase inhibitor squalestatin or the 3-hydroxy-3-methylglutaryl co-enzyme A reductase 
inhibitors fluvastatin or lovastatin (19-21). This induction can be prevented by replenishing 
cholesterol-levels with oxysterols. The same results were obtained with chicken CYP2H1 and 
CYP3A37 mRNA in the chicken hepatoma cell line LMH (22). In the CYP2H1 5’-flanking region, 
a 264-bp PB-responsive enhancer unit (PBRU) was isolated and within this enhancer fragment, a 
DR-4 element was identified to be essential for conferring drug-induction (14). We therefore tested 
if inhibition of CYP2H1 induction by oxysterols is mediated by this PBRU. 
 
As shown in Fig. 1a, both the PB- and the clotrimazole-induction were reduced when co-incubated 
with either 10 M 22(R)-hydroxycholesterol (22R), 24(S)-hydroxycholesterol (24S) or 20 M 25-
hydroxycholesterol (25O) whereas none of the oxysterols affected the CYP2H1 264-bp PBRU 
alone. We also tested the effect of bile acids on the CYP2H1 264-bp PBRU because bile acids are 
able to induce CYP2H1 and CYP3A37 mRNA (22). At 100 M, concentrations that physiologically 
occur in bile or in cholestatic livers (23,24), cholic acid (CA), deoxycholic acid (DCA) and 
chenodeoxycholic acid (CCA) all induced CAT reporter gene levels driven by the 264-bp PBRU in 
LMH cells (Fig. 1b). Surprisingly, co-incubation of these bile acids with PB or clotrimazole 
reduced the effect of the drugs (data not shown). Thus, both oxysterols and bile acids modulate 
drug-induction of the 264-bp PBRU comparable to their effects on CYP2H1 mRNA (22). 
 
The 264-bp PBRU is activated by the chicken xenobiotic-sensing orphan nuclear receptor CXR (9). 
We therefore tested if oxysterols or bile acids directly affect this receptor. An expression vector for 
GAL4(DBD)-CXR(LBD) fusion proteins together with the GAL4 upstream activating sequence 
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(UAS) in a reporter gene vector were co-transfected into CV-1 cells and reporter gene levels 
measured after incubation with drugs, oxysterols or bile acids. As shown in Fig. 1c, none of the 
oxysterols had an inhibitory effect on either PB- or clotrimazole-induction of the CXR-LBD. In 
contrast, the CXR-LBD was activated by the bile acids DCA and CCA (Fig. 1d). Apparently, the 
inhibition of the CYP2H1 264-bp PBRU by oxysterols is not directly mediated by CXR whereas 
CXR itself constitutes a low-affinity bile acid receptor. 
 
Competition between LXR and CXR 
In order to be able to test candidate receptors that might be responsible for the oxysterol and bile 
acid effects, we cloned the chicken LXR and chicken FXR orthologs. A cloning strategy similar to 
the one used for the isolation of chicken CXR was designed (9). Binding of the chicken CXR, LXR 
and FXR to the CYP2H1 264-bp PBRU was examined to see if the observed effects of oxysterols 
and bile acids on drug-induction are directly mediated by these receptors. Electromobility-shift 
assays with radiolabeled 264-bp PBRU as probe showed that neither the chicken RXR, CXR, LXR 
nor FXR bound alone to this enhancer element (Fig. 2a, lanes 2-5). Heterodimers of CXR or LXR 
with RXR shifted the probe (lanes 6 and 8, arrow b) and this complex could be supershifted when 
adding anti-RXR antibody (lanes 9 and 11, arrow c). In contrast, FXR was not able to bind to the 
264-bp PBRU together with RXR (lanes 7 and 10). Thus, multiple chicken nuclear receptors are 
able to bind to this PBRU and others found in the CYP2H1 5’-flanking region (15). 
 
Based on the observed LXR interaction with the CYP2H1 264-bp PBRU, we examined whether 
CXR and LXR bind to the same DR-4 element within this PBRU that has previously been shown to 
be responsible for CYP induction by CXR (9). In electromobility-shift assays, CXR/RXR 
heterodimers bound strongly to the radiolabeled, wildtype 264-bp PBRU and much weaker to the 
radiolabeled 264-bp PBRU containing mutations in both hexamer half-sites of the DR-4 element 
(Fig. 2b, lanes 3 and 5, arrow b). Similarly, LXR/RXR heterodimers only bound to the wildtype 
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264-bp PBRU but not to the DR-4 mutant (lanes 4 and 6). Apparently, both CXR and LXR 
heterodimerize with RXR and bind to the same sequence elements on the 264-bp PBRU. 
 
Since LXR and CXR bind to the same DR-4 element, electromobility-shift assays were used to 
elucidate if LXR and CXR directly compete for binding to this PBRU. To clearly discriminate 
between complexes containing CXR or LXR, a HA-tag was N-terminally attached to CXR and an 
anti-HA monoclonal antibody was used to supershift complexes that include HA-CXR. Constant 
LXR concentrations were titrated against increasing concentrations of HA-CXR with chicken RXR 
and anti-HA antibody included in all reactions (Fig. 2c, lanes 3-12). With increasing HA-CXR 
levels, a shift that is lower compared to the LXR/RXR shift (lane 2, arrow c) and a supershift 
became gradually visible and the LXR/RXR shift decreased correspondingly (lanes 3-12, arrow b 
for the HA-CXR/RXR shift, arrow c for the LXR/RXR shift and arrow d for the supershift). The 
lower shift (arrow b) and the supershift (arrow d) were also observed in a control reaction with HA-
CXR and RXR (lane 13). Vice versa, in electromobility-shifts using constant amounts of HA-CXR 
and increasing levels of LXR, the HA-CXR/RXR supershift was gradually reduced (Fig. 2d). These 
results imply that LXR and CXR directly compete for heterodimerization with RXR and subsequent 
binding to the DR-4 element in the CYP2H1 264-bp PBRU. 
 
Activators of LXR and RXR synergistically inhibit PB-induction 
Functional evidence for the inhibitory action by LXR was also obtained by experiments in LMH 
cells transfected with the 264-bp PBRU using varying concentrations of 9-cis-retinoic acid. After 16 
hours of treatment, the 264-bp PBRU was only activated by micromolar concentrations of 9-cis-
retinoic acid, much more than required to activate RXR in permissive nuclear receptor heterodimers 
(Fig. 3a). This suggests that CXR is non-permissive like PXR and CAR (25). In LMH cells 
transfected with the 264-bp PBRU, 10 M 22(R)-hydroxycholesterol (22R) or 0.1 M 9-cis-retinoic 
acid (9-cis-RA) only marginally change reporter gene levels after 16 hours (Fig. 3b). In striking 
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contrast, the combination of 22(R)-hydroxycholesterol and 9-cis-retinoic acid synergistically 
inhibits drug-induction of the 264-bp PBRU (Fig. 3b). 
 
Further proof for the involvement of LXR was obtained by treating LMH cells with 25 M 
geranylgeranyl-pyrophosphate (GGPP), an inhibitor of LXR that reduces the interaction between 
LXR and the nuclear receptor coactivator SRC-1 (26,27). GGPP was able to induce the CYP2H1 
264-bp PBRU after a 16 hours treatment (Fig. 3c). These results strongly suggest that the 
permissive oxysterol-receptor LXR (28) is responsible for the oxysterol-mediated inhibition of 
drug-induction. 
 
Hydroxylated bile acids activate LXR 
In mammals, CYP3As and to a lesser extent CYP2Cs and CYP2Bs are capable of hydroxylating 
bile acids (29,30). Moreover, a specific subset of hydroxylated bile acids were shown to induce both 
LXR and LXR in transactivation assays (31). Assuming that chicken CYP2H1 is also involved in 
bile acid hydroxylation, we tested the effect of 6-hydroxylated CCA (hyocholic acid, HC) and 6-
hydroxylated lithocholic acid (hyodeoxycholic acid, HD) on drug-induction of the CYP2H1 264-bp 
PBRU and on activation of chicken LXR and FXR, respectively. As depicted in Fig. 4a, 10 M 
hyocholic acid (HC) or hyodeoxycholic acid (HD) had no effect on the CYP2H1 264-bp PBRU 
alone but both compounds severely reduced PB- and clotrimazole-induction comparable to 10 M 
24(S)-hydroxycholesterol (24S) after 16 hours induction in LMH cells. 
 
In CV-1 cell transactivation assays with the GAL4(DBD)-LXR(LBD) and GAL4(DBD)-
FXR(LBD) fusion proteins and the GAL4-response element UAS in a reporter gene vector, 
hyocholic acid (HC) and hyodeoxycholic acid (HD) activated the chicken LXR LBD (Fig. 4b). In 
contrast, chicken FXR LBD was not affected by hydroxylated bile acids after 24 hours incubation at 
a dose of 10 M (Fig. 4c). As control compounds, the oxysterols 20-hydroxycholesterol 
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(20M) and 24(S)-hydroxycholesterol (24S, 10 M) strongly activated chicken LXR. The 
oxysterols 19-hydroxycholesterol (19O, 10 M), 22(R)-hydroxycholesterol (22R, 10 M) and 25-
hydroxycholesterol (25O, 20 M) showed relatively small effects (Fig. 4b). Moreover, 25 M 
GGPP inhibited both 24(S)-hydroxycholesterol- and hyodeoxycholic acid-mediated induction of 
LXR (Fig. 4b). Deoxycholic acid (DCA) and chenodeoxycholic acid (CCA) markedly activated the 
chicken FXR-construct GAL4(DBD)-FXR(LBD) in CV-1 cell transactivation assays whereas 
cholic acid (CA) had no effect (Fig. 4c). Thus, chicken LXR and FXR exhibit similar activation 
patterns as their mammalian orthologs (3). These findings suggest that hydroxylated bile acid-
mediated activation of chicken LXR is responsible for the inhibition of the CYP2H1 264-bp PBRU. 
 
Human LXR competes with PXR and CAR 
Having established the crosstalk between LXR and the xenobiotic-sensing orphan nuclear receptor 
CXR in chicken, we wanted to know whether a corresponding regulatory mechanism of LXR 
competing with PXR and CAR exists in man. Accordingly, electromobility-shift assays with 
wildtype and mutated radiolabeled human CYP3A4 XREM (18) and CYP2B6 51-bp PBREM (32) 
showed specific binding of human PXR, human CAR and human LXR, each of these receptors 
heterodimerized with RXR. This binding was only observed when using the wildtype probe but 
not with mutated probe, as shown for the CYP2B6 PBREM (Fig. 5a, lanes 2-7 and lanes 9-14). 
 
PCR amplifications of CV-1 cDNA revealed the presence of LXR, LXR and FXR in this 
monkey kidney epithelial cell line (Fig. 5b, lanes 3-5) whereas expression of neither PXR nor CAR 
could be detected (lanes 1 and 2). Therefore, co-transfection of additional LXR was not needed to 
test the effect of oxysterols on activation of full-length human PXR, human CAR or chicken CXR 
in CV-1 transactivation assays because the same results were obtained with and without co-
transfecting LXR (data not shown). As depicted in Fig. 5c, PXR-triggered activation of a CYP3A4 
PXR-responsive ER-6 element that also contains a DR-4 element (10) and the CYP2B6 51-bp 
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PBREM by 400 M PB could be prevented in co-incubation experiments with 20 M 25-
hydroxycholesterol. In the same set of experiments, CAR could not be activated by PB, but its basal 
activity was decreased by 25-hydroxycholesterol on the CYP3A4 ER-6 and the CYP2B6 51-bp 
PBREM (Fig. 5d). As a control, CXR activation of the CYP2H1 264-bp PBRU by PB was also 
inhibited by 25-hydroxycholesterol (Fig. 5e) suggesting that the crosstalk between LXR and 
xenobiotic-sensing receptors is a common mechanism conserved from birds to man. 
 
Phenobarbital represses expression of chicken CYP7A1 
Our results thus demonstrate an antagonistic effect of the cholesterol-sensor LXR and the 
xenosensors PXR, CAR and CXR on the expression of drug-induced CYPs. Inversely, LXR 
upregulates mRNA levels of CYP7A1 whereas several findings suggest a PXR-dependent 
repression of CYP7A1 by Cyp3a inducers in mouse (33). Accordingly, we tested if the 
diametrically oposed effects of LXR and xenosensors is also observed in chicken. Total RNA from 
LMH cells treated for 24 hours with either vehicle, 400 M PB, 20 M 25-hydroxycholesterol (25-
OHC) or 100 M CCA was isolated and subjected to Northern hybridization using probes against 
chicken CYP7A1 and chicken GAPDH. As shown in Fig. 6, chicken CYP7A1 expression levels are 
markedly reduced both in LMH cells treated with bile acids and with PB correlating well with the 
results found in mammals with PXR-activators. Interestingly, chicken CYP7A1 mRNA is neither 
induced by 25-hydroxycholesterol (Fig. 6) nor by 24(S)-hydroxycholesterol (data not shown), 
unlike rodent Cyp7a1 but similar to human CYP7A1 (34). 
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Discussion 
 
In the present study, a regulatory interaction between endogenous cholesterol- and bile acid-
homeostasis signaling pathways and drug-mediated induction of CYPs is established. Our data 
show that the oxysterol-sensor LXR controls activation of drug-sensitive enhancer elements by 
competing with the xenobiotic-sensing orphan nuclear receptors CXR, PXR and CAR. These 
receptors compete activating or inhibiting drug-activated enhancer elements, respectively. Our 
findings therefore indicate a direct molecular link between hepatic cholesterol levels and drug- or 
xenobiotic-induction of CYPs. 
 
A significant part of hepatic cholesterol is metabolized to bile acids. Bile acids are important 
regulators of cholesterol homeostasis by inhibiting hepatic cholesterol metabolism into bile acids or 
by enhancing uptake of dietary cholesterol. Thus, the levels of bile acids and cholesterol are linked 
and tightly controlled. This link occurs at the level of transcriptional regulation of CYP7A1 via the 
positively acting oxysterol-receptor LXR in rodents and is opposed by the negative effect of bile 
acids and the bile-acid receptor FXR (7,8) (Fig. 7a). Under pathological conditions such as 
cholestasis, bile acids accumulate in the liver and cause cell damage. Additional mechanisms are 
needed under these conditions for bile acid metabolism and excretion. Here, we show that the 
xenobiotic-sensing nuclear receptor CXR is a low affinity bile acid-receptor and is therefore 
capable of inducing CYP2H1 and CYP3A37 in the presence of high bile acid levels in a chicken 
hepatoma cell line. In mouse and man, the xenosensor PXR is also activated by high bile acid levels 
and plays a role in prevention of bile acid-induced hepatotoxicity (13,17). Thus, when bile acids 
accumulate in the liver and reach toxic concentrations, they activate xenobiotic-sensing nuclear 
receptors and stimulate their own metabolism into more hydrophilic hydroxylated bile acids which 
are renaly excreted. This concept has recently been demonstrated in the FXR-null mouse where bile 
acid export into bile is reduced and thus leads to elevated hepatic bile acid levels (35). Strikingly, 
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hydroxylated bile acids inhibit drug-activation of drug- and bile acid-metabolizing CYPs and 
therefore directly regulate their own levels in the liver. In this report, we could show that 
hydroxylated bile acids activate the oxysterol-sensor LXR. Therefore, the inhibitory effects of 
oxysterols and hydroxylated bile acids are mediated by the same mechanism. Both in chicken and in 
mouse (3,13), drugs activating PXR or CXR negatively affect the transcript level of CYP7A1, 
thereby inhibiting the biosynthesis of bile acids from cholesterol but also potentially elevating 
plasma cholesterol levels. Consequently, we propose a novel regulatory mechanisms by which the 
levels of cholesterol, bile acids and hydroxylated bile acids in the liver are regulated by both drug-
activated transcription factors and the oxysterol-sensing nuclear receptors (Fig. 7b). In conjunction 
with drug- and bile acid-metabolizing CYPs, phase II enzymes and transporters are activated by 
xenosensors which therefore control a whole enzyme battery for metabolism and clearance of high 
levels of lipophilic, toxic compounds (13,36,37). 
 
This is the first report describing inhibition of gene expression by LXR/RXR heterodimers on a 
DR-4 element. The mechanistic explanation for this inhibition has not been elucidated yet and is 
under current investigation. Moreover, the results reported here have been obtained in in vitro 
assays such as cell culture or electromobility shift assays. Verification of the hypothesis of LXR-
CXR/PXR/CAR crosstalk in drug-inducible CYP induction is currently being studied using mouse 
models with deficiencies in the respective receptors. However, our hypothesis is supported by 
numerous in vivo experimental and clinical observations. As examples, treatment with the inhibitors 
of cholesterol biosynthesis squalestatin, lovastatin or fluvastatin induces CYP2B1/2 in primary rat 
hepatocytes or rat liver in vivo (19-21). Rats fed a high cholesterol diet or spontaneous 
hyperlipidemic rats with 3-4 fold increased cholesterol levels have lower expression of basal and 
PB-induced CYPs compared to control animals (38,39) and exhibit changes the expression of 
several enzymes encoding cholesterol-synthesizing and metabolizing enzymes (40,41). Obese fa/fa 
Zucker rats fail to exhibit a significant induction response of CYP2B1/2 after PB-treatment (42). 
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PB-treatment of epileptic patients or of rats resulted in increased plasma cholesterol- and 
lipoprotein-levels (43-48). Similarly, HIV-protease inhibitor therapy in AIDS patients often leads to 
elevated cholesterol and triglyceride levels. Among the current protease inhibitors, ritonavir is 
associated with the highest frequency of hypercholesterolemia in contrast to saquinavir, indinavir or 
nelfinavir which are reported to have markedly lower relative risks for hypercholesterolemia (49). 
Recently, ritonavir has been shown to bind to and to activate human PXR whereas saquinavir is a 
weak activator and nelfinavir and indinavir do not affect PXR at all (50). The present results now 
offer an explanation for these clinical observations. 
 
Under normal conditions and in cholestasis, CCA and hyocholic acid, respectively, belong to the 
major components of bile in human and rat hepatocytes (23,24). Moreover, hyocholic and 
hyodeoxycholic acid are also found in the serum and urine of cholestatic patients treated with PB or 
rifampicin (51-53). For years, cholestatic patients have been empirically treated with PB or 
rifampicin without knowing the molecular mechanism underlying the beneficial effect (51,54). The 
antagonistic effect of oxysterol-activated LXR on drug-induced CYPs by the xenobiotic-sensing 
nuclear receptors CXR, CAR and PXR and the activation of these transcription factors by bile acids 
now provides an explanation for the clinical remission of cholestatic symptoms in patients after 
drug-treatment. Metabolic disorders affecting cholesterol homeostasis such as hypercholesterolemia 
or hypertriglyceridemia are prevalent in industrialized countries and are associated with serious 
diseases like atherosclerosis, cardiovascular disorders or adult-onset diabetes. The nuclear receptors 
LXR and FXR are attractive new drug-targets for treatment of some of these diseases (55). For 
example, activation of LXR in macrophages has been described to reduce atherosclerosis and 
plasma LDL-levels by inducing the transcription of ABC-type transporters and apolipoprotein E 
(56,57). We and others (31) found that a subset of hydroxylated bile acids activate LXR. 
Accordingly, administered hyocholic acid efficiently suppresses atherosclerosis formation and 
lowers plasma cholesterol levels in mice (58). Nevertheless, due to the crosstalk of these receptors 
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with the hepatic detoxification system, potential adverse drug reactions have to be considered, e. g. 
in cholesterol-lowering therapies using a combination of LXR agonists which decrease the LDL- 
and increase the HDL-part of the cholesterol together with statins that lower de novo biosynthesis. 
 
Our studies thus support the concept that the molecular mechanism of hepatic drug-induction is 
closely linked to endogenous regulatory pathways. This leads to speculations about the evolutionary 
origin of drug-metabolizing CYPs and xenobiotic-sensing nuclear receptors. Many of the drug-
metabolizing CYPs also catalyze the biotransformation of steroid hormones and bile acids. Long-
term treatment with inducer compounds drastically alters steroid metabolism and elevates steroid 
clearance (59). The findings reported here also demonstrate an influence of cholesterol and bile acid 
levels on hepatic drug-metabolism. Certain bile acids activate the detoxification system whereas 
other cholesterol metabolites such as oxysterols or hydroxylated bile acids reduce the corresponding 
CYP expression. The system of these nuclear receptors and CYPs probably evolved to handle 
accumulated toxic cholesterol metabolites that have detergent properties. Later, both these nuclear 
receptors and the CYPs may have extended their substrate specificity to include xenobiotic 
compounds with similar hydrophobic properties. Seemingly, our body deals with drugs and other 
xenobiotics by handling them as “toxic bile acids”. 
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Figure Legends 
 
FIG 1. Oxysterols and bile acids modulate drug-induction of the CYP2H1 264-bp PBRU and 
of CXR mediated transactivation. a, A reporter gene vector containing the chicken CYP2H1 264-
bp PBRU was transfected into LMH cells cultured for 24 hours in medium lacking serum. Cells 
were subsequently treated for 16 hours with either vehicle (0.1 % DMSO), 400 M PB, 10 M 
clotrimazole, 10 M 22(R)-hydroxycholesterol (22R), 10 M 24(S)-hydroxycholesterol (24S) or 20 
M 25-hydroxycholesterol (25O) or combinations of these compounds. The relative CAT 
expression was standardized against untreated control cells and expressed as fold induction. b, 
Transfected LMH cells were treated with 100 M cholic acid (CA), 100 M deoxycholic acid 
(DCA), 100 M chenodeoxycholic acid (CCA) or 400 M PB. c, CV-1 cells were co-transfected 
with the GAL4(DBD)/CXR(LBD) fusion proteins and with the (UAS)5-tk-CAT reporter gene 
plasmid. Cells were then treated either with vehicle (0.1 % DMSO), 400 M phenobarbital, 10 M 
clotrimazole, 10 M 20-hydroxycholesterol (20), 10 M 22(R)-hydroxycholesterol (22R), 10 
M 24(S)-hydroxycholesterol (24S) or 20 M 25-hydroxycholesterol (25O) alone or in 
combinations for 24 hours. Cell extracts were analyzed for CAT expression normalized against -
galactosidase levels. d, Transfected CV-1 cells were treated with 100 M cholic acid (CA), 100 M 
deoxycholic acid (DCA), 100 M chenodeoxycholic acid (CCA) or 400 M PB. Values are the 
mean of three independent experiments, and bars represent standard deviation. 
 
FIG 2. CXR and LXR, but not FXR, compete for binding to the same DR-4 element within 
the CYP2H1 264-bp PBRU. a, Radiolabeled 264-bp PBRU was incubated with in vitro 
transcribed/translated CXR (lanes 3, 6 and 9), FXR (lanes 4, 7 and 10), LXR (lanes 5, 8 and 11), 
chicken RXR (lanes 2 and 6-11) and anti-RXR antibody (lanes 9-11). Arrows depict the unbound 
probe (a), the complex of CXR and LXR with RXR (b) and the supershift of these complexes after 
addition of anti-RXR antibody (c). b, Radiolabeled wildtype 264-bp PBRU (wildtype, lanes 1, 3 
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and 4) or radiolabeled 264-bp PBRU with a double mutation in the DR-4 site (double, lanes 2, 5 
and 6) were incubated with in vitro transcribed/translated CXR (lanes 3 and 5), LXR (lanes 4 and 6) 
and chicken RXR (lanes 3-6). Arrows depict the unbound probe (a) and the complex of CXR and 
LXR with RXR (b). c, Radiolabeled wildtype 264-bp PBRU was incubated with in vitro 
transcribed/translated CXR containing an N-terminal hemagglutinin-tag (HA-CXR) (lanes 3-13), 
chicken LXR (lanes 2-12), chicken RXR (lanes 2-13) and anti-HA antibody (lanes 2-13) as 
indicated. Increasing HA-CXR concentrations were applied from lane 3 to lane 12. Arrows depict 
the unbound probe (a), the complex of HA-CXR with RXR (b), the shift of the LXR/RXR 
complex bound to the 264-bp PBRU (c) and the supershift of HA-CXR and RXR together with 
anti-HA antibody (d). d, Electromobility-shifts with increasing concentrations of LXR from lane 3 
to lane 13 and constant concentrations of HA-CXR in lanes 2-12. 
 
FIG 3. Oxysterols and 9-cis-retinoic acid synergistically inhibit drug-induction of the 
CYP2H1 264-bp PBRU. a, The chicken CYP2H1 264-bp PBRU was transfected into LMH cells 
that had been cultured for 24 hours in medium without serum. Cells were subsequently treated for 
16 hours with either vehicle (0.1 % DMSO), 400 M PB or increasing concentrations of 9-cis-
retinoic acid (0.1 nM–10 M). Cells were harvested and CAT levels determined. The relative CAT 
expression was standardized against PB-treated cells and expressed in percentage of PB-induction. 
b, LMH transfected with the 264-bp PBRU were treated for 16 hours with vehicle, 400 M PB, 10 
M 22(R)-hydroxycholesterol (22R), 0.1 M 9-cis-retinoic acid (9-cis-RA) or combinations of 
these drugs. The relative CAT expression was standardized against untreated cells and expressed as 
fold induction. Values are the mean of three independent experiments, and bars represent standard 
deviation. c, Transfected LMH cells were treated with 400 M phenobarbital (PB) or 25 M of the 
LXR-inhibitor geranylgeranyl-pyrophosphate (GGPP) for 16 hours before CAT levels were 
measured. 
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FIG 4. Hydroxylated bile acids repress drug-induction of the CYP2H1 264-bp PBRU and 
activate LXR. a, The chicken CYP2H1 264-bp PBRU was transfected into LMH cells that had 
been cultured for 24 hours in medium lacking serum. Cells were subsequently treated for 16 hours 
with either vehicle (0.1 % DMSO), 400 M PB, 10 M clotrimazole, 10 M 24(S)-
hydroxycholesterol (24S), 10 M hyocholic acid (HC), 10 M hyodeoxycholic acid (HD) or 
combinations of these compounds. The relative CAT expression was standardized against untreated 
cells and expressed as fold induction. b, c, CV-1 cells were co-transfected with the GAL4(DBD)-
LXR(LBD) (Fig. 4b) or the GAL4(DBD)-FXR(LBD) (Fig. 4c) fusion proteins, respectively, 
together with the reporter gene plasmid (UAS)5-tk-CAT. Cells were subsequently treated either 
with vehicle (0.1 % DMSO), 10 M 19-hydroxycholesterol (19O), 10 M 20-hydroxycholesterol 
(20), 10 M 24(S)-hydroxycholesterol (24S), 10 M 22(R)-hydroxycholesterol (22R), 20 M 25-
hydroxycholesterol (25O), 10 M cholic acid (CA), 10 M deoxycholic acid (DCA) or 10 M 
chenodeoxycholic acid (CCA), 10 M hyocholic acid (HC), 10 M hyodeoxycholic acid (HD), 25 
M geranylgeranyl pyrophosphate (GGPP) or combinations of these drugs for 24 hours. Cell 
extracts were analyzed for CAT expression normalized against -galactosidase levels. Values 
represent the mean of three independent experiments, and bars represent standard deviation. 
 
FIG 5. Human LXR inhibits drug-activation of the human CYP3A4 and CYP2B6 PB-
responsive enhancer elements by human PXR and CAR. a, Radiolabeled wildtype XREM of 
human CYP3A4 or 51-bp PBREM of CYP2B6 as well as the corresponding PBREM sequence 
containing a double mutation in the DR-4 context were incubated with in vitro 
transcribed/translated human PXR, CAR or LXR together with RXR. b, Amplification of 
nuclear receptors from cDNA of CV-1 cells. Specific primers against human CAR (lane 1), PXR 
(lane 2), LXR (lane 3), LXR (lane 4), FXR (lane 5) and of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH, lane 6) were used for PCR reactions using CV-1 cell cDNA as template. 
Regions of the expected sizes were excised, subcloned and sequenced to confirm the identity of the 
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bands as described in the Methods section. c, d, e, CV-1 cells were co-transfected with either 
human PXR (c), human CAR (d) or chicken CXR (e) together with the CYP3A4 ER-6, CYP2B6 
51-bp PBREM and the CYP2H1 264-bp PBRU, respectively. After treatment with vehicle (0.1% 
DMSO), 400 M phenobarbital, 10 M 25-hydroxycholesterol or combinations of these drugs for 
24 hours, cell extracts were analyzed for CAT expression normalized against -galactosidase levels. 
Values are the mean of three independent experiments, and bars represent standard deviation. 
 
FIG 6. Chicken CYP7A1 expression is inhibited by bile acids and phenobarbital. Total RNA 
from LMH cells treated with vehicle, 400 M PB, 20 M 25-hydroxycholesterol (25-OHC) or 100 
M CCA was isolated and analyzed on blots probed with radiolabeled chicken CYP7A1 or chicken 
GAPDH. 
 
FIG 7. Proposed regulatory interplay between drug-metabolising CYPs and cholesterol- as 
well as bile acid-homeostasis under normal and pathological conditions. a, Under normal 
conditions, cholesterol controls its metabolism to bile acids by activating LXR in rodents. High bile 
acid levels consequently reduce this pathway by inhibiting CYP7A1, the first and rate-limiting 
enzyme in bile acid biosynthesis. This inhibition is dependent on FXR. Bile acids are 
predominantly excreted via bile and feces. b, When bile acids accumulate in the liver, they also 
activate the drug-sensing nuclear receptors CXR in chicken as well as PXR and potentially CAR in 
mammals. Subsequently, bile acids are hydroxylated by CYPs of the subfamilies CYP3A/2B/2C 
and 2H and can then be excreted via blood and urine. High levels of hydroxylated bile acids activate 
LXR which competes with the xenosensors CXR, PXR and CAR for binding to enhancer elements 
in the 5’-flanking regions of these CYPs. PXR, CXR and CAR also inhibit formation of bile acids 
by negative regulation of CYP7A1 by so far unknown mechanisms. 
 
